Unless they ignore it completely, the process seems long; like over a year of potential banter, appeals, etc..
What matters most is finishing up whatever IND enabling that has been in progress, securing grant funding and inking partners/resources/funding as they plan and move into multiple human clinical trials.
Leverage that progress into fair market valuation that will provide flexibility to assist in pushing the ampakine and OSA platform forward, which both have stalled potential.
Bring in some actual management that knows how to communicate and present the company and the assets properly.
Sitting at a 1 million + or - valuation for several years is disappointing on so many levels considering their science approach and positioning is smart and promising and peer reviewed publications highlight great potential
Market Data 
Markets 
AI
